Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI ACWI ETF (ACWI) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

iShares MSCI ACWI ETFTrade
Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI ACWI ETF vs Amylx Pharmaceuticals Inc — how do they compare? iShares MSCI ACWI ETF trades at $161.79, while Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B). Which is the better fit depends on your goals.

ACWIAMLX
52-Week High
$161.44$24.19
52-Week Low
$132.04$7.82
Market Cap
$2.64B
Sector
Health
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI ACWI ETF

ACWI trades at $161.72, up 0.38% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF's forward P/E of 15.5x, as of Seeking Alpha on 2026-07-07, suggests reasonable valuation amid robust earnings growth, with Information Technology now comprising 32% of holdings. A dividend of $1.01 is scheduled for June 2026.

Outlook remains positive due to strong EPS growth and institutional interest, though overbought RSI levels near 74.95 signal caution. Risks include market volatility from AI-driven inflows and potential sector concentration, but analyst sentiment supports a buy rating for long-term global equity exposure.

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Returns comparison

Trailing returns across standard periods

About iShares MSCI ACWI ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.

Read more on ACWI

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX